Life Science Success

Send us Fan Mail

In this episode of Life Science Success, my guest is Tom Hartman.  Tom is the President and CEO of the International Society of Pharmaceutical Engineering (ISPE), Tom leads a global network of 20,000+ professionals spanning the complete pharmaceutical lifecycle.

In this edition of Life Science Success, Don Davis interviews Tom Hartman, the president and CEO of the International Society of Pharmaceutical Engineering (ISPE). They discuss Hartman's career journey and the role of the ISPE in the life sciences industry. Hartman discusses the critical role of the society's volunteer network and emphasizes the importance of speed, quality, and solid decision-making in the industry. Concerns about industry shortages, workforce challenges, and readiness for future potential pandemics also arise. Hartman highlights several exciting incursions, such as the 'Facility of the Year Award' and ISPE's workforce of the future initiative. The interview sheds light on the ISPE's strategic goals and the overall current industry landscape and trends.

Send us Fan Mail

In this episode of the Life Science Success Podcast my guests are James Foster, CEO of Virax Labs and Nigel McCracken COO of Virax Labs.  Virax Labs is a global biotechnology company specializing in the development of innovative diagnostic solutions. They focus on T-cell testing and immune profiling, with a novel portfolio of FluoroSpot T-cell diagnostics aimed at indications associated with chronic inflammation and T-cell exhaustion.

• Podcast Overview: The first "Life Science Success" podcast episode in 2024 features James Foster, CEO, and Nigel McCracken, COO, of Virax Biolabs. 

• James Foster's Background: James Foster, CEO of Virax Biolabs, co-founded the company about 10 years ago. Initially starting in finance, he shifted to biotech and diagnostics due to his entrepreneurial interests, particularly influenced by the 2008 financial crisis. His goal is to develop comprehensive immune profiling in-vitro diagnostics (IVDs), focusing on early diagnosis of post-viral syndromes, chronic inflammation, and T-cell exhaustion.

• Virax Biolabs' Mission and Technology: Virax is dedicated to creating innovative diagnostic solutions, particularly their T-cell testing platform. This platform aims to address significant health issues like long COVID, affecting millions in the US and Europe. Foster emphasizes the importance of early detection in disease progression and the role of the immune system in combating pathogens.

• Nigel McCracken's Role and Insights: As COO, Nigel McCracken plays a crucial role in scaling Virax from a small team to a larger organization. He discusses the importance of strategic focus, effective decision-making, and the development of companion diagnostics, which are essential for personalized medicine, especially in oncology.

• Future Outlook and Challenges: Both Foster and McCracken highlight the challenges in biotech, including the need for innovation, execution, and efficient leadership. They foresee an increasing burden on healthcare systems due to post-viral syndromes and chronic conditions. The podcast also touches on the potential of venture capital in fostering new ideas and innovations in the biotech sector.

Send us Fan Mail

In this episode of Life Science Success, we are welcoming back Dr. AJ Mellott. Dr. Mellott is the CEO and Co-Founder, Ronawk manufacturer of customized tissue-mimetic technology that is advancing science.

1. Dr. AJ Mellott is the CEO and co-founder of Ronawk, a company that specializes in creating hydrogel substrates that mimic various tissues in the human or animal body.
2. Ronawk's tissue mimetic technology is used in cell culture to produce high-quality, active cells that are valuable for medical and diagnostic applications.
3. The company has recently expanded and moved to Overland Park, Kansas, and has experienced significant growth in its team and production practices.
4. Ronawk's technology has facilitated collaborations between researchers in different fields and has lowered barriers to experimentation and innovation in the life sciences.
5. Dr. Mellott is excited about the potential of AI and machine learning to streamline research processes and the personalized screening of therapies for patients, ultimately improving healthcare outcomes.

Send us Fan Mail

In this episode of Life Science Success, my guest is Dr Paul Song. Dr. Song has served as Chief Executive Officer and Vice Chairman of NKGen since December 2022.

1. Dr. Paul Song, CEO and Vice Chairman of NKGen since December 2022, shares his background as a radiation oncologist and his journey into biotech.
2. Dr. Song talks about the importance of natural killer cells in the body's defense against diseases and their potential in treating conditions like Alzheimer's.
3. NKGen's phase one trial showed promising results, with 90% of patients either stabilizing or improving in Alzheimer's treatment.
4. NKGen is also exploring the use of natural killer cells in combination with other cancer therapies to enhance their effectiveness while minimizing side effects.

Send us Fan Mail

In this episode of Life Science Success, we are talking about Securing America's Pharmaceutical Supply with David Sanders and Tony Paquin.  We are going to discuss derisking the supply chain and building resilience.

Don, is joined by guests, David Sanders and Tony Paquin. They discuss the importance and challenges of securing America's medical supply chain. David introduces himself as the Vice President of Government Affairs at Coherence Biosciences and Executive Director at Securing America's Medicine and Supply, and Tony as the CEO and co-founder of iRemedy Healthcare, an AI-driven supply chain platform. They delve into the impacts of the COVID-19 pandemic on these supply chains, their effort in repatriating pharmaceutical supply and manufacturing back in America, and the role of innovation in overcoming the costs and barriers involved. Tony also mentioned his book, "The End of Us," which talks about this same issue.

Send us Fan Mail

My guest today on the Life Science Success Podcast is Andrea Henderson.  Andrea is a Partner in the Life Sciences, Healthcare, Diversity, CEO & Board practices at DHR Global where she is an executive talent solutions strategist.

Andrea Henderson, an Executive Talent Solutions Strategist, and they delve into Andrea's career journey, which started with a passion for diplomacy and evolved into a focus on talent management and diversity in the corporate world.

Key Takeaways:

1. Operational Excellence: Don emphasizes the significance of operational excellence in the life sciences industry, particularly the importance of value stream mapping.

2. Career Evolution: Andrea's career journey highlights the unpredictable nature of career paths. Her transition from diplomacy to talent management and executive search underscores the importance of adaptability and problem-solving skills.

3. Diversity and Inclusion: Andrea discusses the role of diversity and inclusion in executive-level roles, emphasizing the need to consider a wide range of perspectives to build the best teams.

4. Impactful Leadership: Don and Andrea touch on leadership styles, with Andrea describing her leadership style as collaborative, visionary, and empowering. They also discuss the importance of authenticity, trust-building, and clear communication in leadership.

5. Championing Change: Andrea expresses her excitement about the various avenues available to impact the future, particularly in promoting diversity and creating a more inclusive corporate environment.

Send us Fan Mail

In this episode of Life Science Success, my guest is Sucheshna Patil.  She is the CEO and founder of MobilityZ Health. A health-focused biotech engineer, innovator, and researcher building health technology products.

1. Mobility Z Health's Focus: The company specializes in orthopedic care, particularly addressing the problem of delays in orthopedic appointments. Their goal is to provide early care and diagnosis for musculoskeletal injuries, reducing backlogs in orthopedic care.

2. Transition from Humans in Space: Although the company initially operated as "Humans in Space," it later transitioned to the name "Mobility Z Health" to better align with its focus on healthcare and orthopedic solutions.

3. Multifaceted Background: Sucheshna Patil has a background as a biotech engineer and researcher, with a passion for healthcare innovation. She drew from her experiences in healthcare, research, and engineering to develop solutions for musculoskeletal injuries.

4. User-Friendly Approach: Mobility Z Health places a strong emphasis on user experience and user-friendliness in its products to ensure that a wide range of people, including patients and older generations, can use them.

5. Development Stage: The company is currently in the alpha testing phase, with private access for patients and doctors who want to use the product. A beta version for broader consumer use is expected to launch in January.

Send us Fan Mail

In this episode of Life Science Success, my guest is Mara Holinger.  Mara is the SVP and co-founder of Quantum Regulatory Solutions.  She has extensive experience in assisting pharmaceutical and biotech firms with preparing their regulatory pathway, providing regulatory input for clinical trial designs and clinical development plans, performing gap analyses for preclinical testing and writing regulatory applications.

Key points covered in this interview: 

1. Background and Expertise: Mara Holinger has a strong background in Regulatory Affairs, with a Ph.D. in a related field. She also highlighted her co-founders' scientific expertise, making their team unique in the regulatory consulting field.

2. Client Base: Quantum Regulatory Solutions primarily serves small to midsize pharmaceutical companies, offering a range of services beyond just regulatory strategy, including pre-meeting support and long-term pathway planning.

3. Team Collaboration: Mara emphasized the importance of collaboration within her team, combining their diverse skill sets to provide comprehensive solutions to clients. This collaborative approach sets them apart from others in the field.

4. Leadership and Empowerment: She mentioned the value of strong leadership and role models who encouraged her to speak up and not apologize for her opinions. This empowerment has been crucial in her career.

5. Passion for Problem-Solving: What excites Mara is the opportunity to solve complex puzzles in the regulatory space, working closely with various stakeholders to ensure that innovative therapies can navigate the regulatory process successfully.

Send us Fan Mail

In this episode of Life Science Success, my guest is Cristian Massacesi MD.  Cristian is the Chief Medical Officer & Oncology Chief Development Officer at AstraZeneca.  In the interview, we will discuss his start in oncology, his career path, and current trends in oncology. 

1. Guest Introduction: Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer at AstraZeneca. The discussion focuses on his career in oncology, his path in the medical field, and current trends in technology.

2. Background and Career Path: Cristian Massacesi, originally from Italy, pursued a career in oncology due to its challenges and potential for impact. After training in Italy, the UK, and the USA, he transitioned from clinical practice to pharmaceutical research, realizing his passion for clinical research.

3. Role at AstraZeneca: In his dual role at AstraZeneca, Massacesi focuses on prioritizing tasks and managing a busy schedule. He works in R&D, particularly in oncology, overseeing the development of safe and effective products, and engaging with various teams globally.

4. Clinical Trials and Leadership: Massacesi emphasizes the importance of clinical trial diversity and the need for innovation in trial execution. He shares his perspective on leadership, highlighting the necessity of assembling strong teams and being accessible and human in management.

5. Vision and Challenges: He is driven by the goal of defeating cancer and leading an organization towards this aim. Massacesi expresses concerns about the complexity of change management in drug development and the regulatory environment, while also finding excitement in the advancements and recognition in the field.

Send us Fan Mail

In this episode of Life Science Success, my guest is Bob Rochelle the Chief Commercial Officer at Cleveland Diagnostics.  Bob is a proven expert in launch, strategy, and marketing for novel healthcare products. His more than 30 years of experience ranges from start-ups such as Exact Sciences and Good Start Genetics to established multinationals such as Abbott Laboratories.

1. Introduction of Bob Rochelle: The episode of "Life Science Success" features Bob Rochelle, Chief Commercial Officer at Cleveland Diagnostics. Rochelle is recognized for his expertise in launch strategy and marketing for novel healthcare products.

2. Bob Rochelle's Background: With 35 years in the healthcare industry, Rochelle has extensive experience, primarily in diagnostics, working with both pharmaceuticals and startups. His career includes roles in various therapeutic and diagnostic areas, from antibiotics and antihypertensive drugs to genetic disease diagnostics and cancer.

3. Transition to Startups: Rochelle discusses his transition from large corporations like Abbott Laboratories to smaller startups. He emphasizes the appeal of being able to rapidly implement ideas and the challenges of limited resources compared to larger companies.

4. Cleveland Diagnostics and Novel Technology: At Cleveland Diagnostics, Rochelle is involved with a novel platform technology for cancer diagnostics. He highlights the importance of innovative technology and a strong team in his career choices.

5. Insights on Cancer Diagnostics and Career Lessons: Rochelle shares insights on the evolution of cancer diagnostics, emphasizing the importance of specificity and sensitivity in tests like isopsa for prostate cancer. He reflects on lessons learned throughout his career, including the significance of diverse perspectives in small companies and the challenges of navigating healthcare reimbursement systems.